AB Science: publication of preclinical data on the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AB Science: publication of preclinical data on the neuroprotective effect of masitinib

PARIS, Oct. 30, 2014 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the publication of preclinical study results with masitinib in ischemic stroke. Entitled, ' Neuroprotective effect of masitinib in rats with postischemic stroke ' this article and its accompanying supplementary information are freely accessible online from the peer-reviewed journal Naunyn-Schmiedeberg's Archives of Pharmacology: http://link.springer.com/article/10.1007%2Fs00210-014-1061-6

  • Findings showed that masitinib reduced stroke-related brain infarct size in an animal model of stroke.
  • Masitinib may be recommended as an appropriate candidate for further development of novel neuroprotective strategies, including in acute ischemic stroke.

Dr. Ivan Kocic, principal author of this publication declared: "Mast cells are present on both sides of the blood brain barrier (BBB) and interact with neurons, glia, blood vessels, and other hematopoietic cell. Mast cells disrupt the permeability of the BBB when they degranulate. Mast cells are also involved in neuro inflammation responsible for neuronal alteration and engage in cross-talk with microglia and astrocytes. Masitinib, by blocking mast cell degranulation on the blood side of the BBB (i.e. extracerebral), may restore integrity of the BBB and reduce neuro-inflammation. This preclinical study, showing the potential of masitinib to improve therapeutic outcome of ischemic stroke, most probably via preservation of BBB integrity, provides further evidence of masitinib's prospective role in neurodegenerative diseases."

Masitinib is under development in numerous neurological indications, including Alzheimer's disease, progressive multiple sclerosis and amyotrophic lateral sclerosis (ALS), for which there is evidence that mast cells actively participate in pathogenesis, in particular through modulation of the BBB. These current results in ischemic stroke provide further evidence that masitinib can potentially offer an innovative therapeutic solution to neurodegenerative diseases with high medical need.

About masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment in cancers, inflammatory diseases, and central nervous system diseases, both in human and animal health.

AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA. The company is currently pursuing thirteen phase 3 studies in human medicine in first-line and second-line GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, metastatic colorectal cancer, metastatic prostate cancer, pancreatic cancer, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science's website: www.ab-science.com

This document contains prospective information. No guarantee can be given as for the realization of these forecasts, which are subject to those risks described in documents deposited by the Company to the Authority of the financial markets, including trends of the economic conjuncture, the financial markets and the markets on which AB Science is present.

*   *   *

AB Science - Financial Communication & Media Relations
contact@ab-science.com

AB Science EN http://hugin.info/155655/R/1867361/656134.pdf

HUG#1867361

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 175

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 34

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 16

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 211

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 0

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 120

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 77

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 0

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

A.B. Data Appoints Steve Straub as New Operations VP

Updated Category News Views 542

A.B. Data Appoints Steve Straub as New Operations VP A.B. Data, a prominent name in class action notice and claims administration, has elevated Steve Straub to the role of Vice President of Operations. Having served as the Senior Director of Operations since 2023, Steve brings a wealth of experience that will further strengthen the company’s operations. Strategic...

Continue Reading
Conexon Connect Expands Fiber Network for Rural Internet Access

Updated Category News Views 170

Conexon Connect's Milestone Achievement Conexon Connect has successfully completed a transformative fiber-to-the-home (FTTH) project, expanding high-speed internet access to over 12,000 members of rural electric cooperatives. This expansive network marks a significant achievement in bridging the digital divide, particularly for underserved communities. Partnerships...

Continue Reading
Xiaomi MIX Flip 2 Unveils TCL CSOT's Cutting-Edge Displays

Updated Category News Views 349

TCL CSOT Powers the Xiaomi MIX Flip 2's Display Experience TCL CSOT is making waves in the tech world by providing state-of-the-art displays for the Xiaomi MIX Flip 2. This new foldable smartphone marks a significant shift in user experiences, aligning perfectly with the growing demand for portable, high-performance devices. During a recent launch event showcasing...

Continue Reading
Immunic Showcases Promising Results for Vidofludimus Calcium

Updated Category News Views 106

Immunic Highlights Key Findings from CALLIPER Trial Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company specializing in innovative oral therapies for neurologic and gastrointestinal conditions, recently presented significant data from its Phase 2 CALLIPER trial. This trial evaluates its cornerstone therapy, vidofludimus calcium (IMU-838), aimed at treating...

Continue Reading
Amrop Expands Global Reach with New Office in Colombia

Updated Category News Views 153

Amrop Expands With a New Office in Colombia Amrop, a distinguished global executive search and leadership consulting firm, has recently announced the establishment of a new office in Colombia. This expansion marks a significant milestone for Amrop as they enhance their service offerings in Latin America. Introducing Amrop Colombia Amrop Colombia emerges from the merger...

Continue Reading